EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Sean Wharton, Louis J Aronne, Adam Stefanski, Nasreen F Alfaris, Andreea Ciudin, Koutaro Yokote, Bruno Halpern iD, Alpana P Shukla, Chunmei Zhou, Lisa Macpherson, Sheryl E Allen, Nadia N Ahmad und 2 weitere

New England Journal of Medicine · 06.11.2025 · 393 (18) · 1796-1806

DOI: 10.1056/nejmoa2511774 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.11.2025. Verfasst von Sean Wharton und 13 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Weight Loss. Die Arbeit wurde bisher 209-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityWeight LossAdultFemaleHumansMaleMiddle AgedAdministration, OralDouble-Blind MethodIntention to Treat AnalysisGastrointestinal DiseasesFluorine CompoundsOxadiazolesTreatment Outcome

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsorforglipronFluorine CompoundsOxadiazoles

Autor:innen und Institutionen

  • McMaster University, Hamilton, ON, Canada.
  • York University, Toronto.
  • Wharton Weight Management Clinic, Burlington, ON, Canada.
  • Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York.
  • Eli Lilly, Indianapolis.
  • Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.

ORCID-Profile: Bruno Halpern

Förderung

  • Eli Lilly and Company

Zitieren

APA

Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., Klise, S. R., & ATTAIN-1 Trial Investigators (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 393(18), 1796-1806. https://doi.org/10.1056/nejmoa2511774

Vancouver

Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025;393(18):1796-1806. doi:10.1056/nejmoa2511774

BibTeX
@article{Wharton2025,
  author = {Wharton, Sean and Aronne, Louis J and Stefanski, Adam and Alfaris, Nasreen F and Ciudin, Andreea and Yokote, Koutaro and Halpern, Bruno and Shukla, Alpana P and Zhou, Chunmei and Macpherson, Lisa and Allen, Sheryl E and Ahmad, Nadia N and Klise, Suzanne R and ATTAIN-1 Trial Investigators, ATTAIN-1 Trial Investigators},
  title = {Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {18},
  pages = {1796--1806},
  doi = {10.1056/nejmoa2511774}
}
Kostenlos starten →